Celldex Therapeutics reported $398.1M in Equity Capital and Reserves for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Abbvie ABBV:US $ 16283M 875M
Agenus AGEN:US $ 15.72M 18.72M
Amgen AMGN:US $ 916M 5784M
Applied Genetic Technologies AGTC:US $ 47.03M 4.46M
Aptinyx Inc APTX:US $ 77.48M 17.27M
Biocept BIOC:US $ 37.03M 0.45M
Bristol Myers Squibb BMY:US $ 31580M 4366M
Celldex Therapeutics CLDX:US $ 398.1M 21.38M
Cytrx CYTR:US 3.28M 1.5M
Glaxosmithkline GSK:US $ 16181M 1126M
Immunogen IMGN:US $ 306.47M 19.12M
Merrimack Pharmaceuticals MACK:US $ 14.08M 112K
Nektar Therapeutics NKTR:US $ 607.89M 71.62M
Newlink Genetics NLNK:US $ 81.82M 7.16M
Northwest Biotherapeutics NWBO:US -120525000 3.47M
Pfizer PFE:US $ 82424M 5224M
Rigel Pharmaceuticals RIGL:US $ 6.8M 23.58M
Seattle Genetics SGEN:US $ 2998.47M 66.67M